Skip to content

Clinical observation for multiple use of tranexamic acid after total knee arthroplasty

Clinical observation for tranexamic acid multiple use after total knee arthroplasty and its effect on inflammatory factors

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR1900002300
Enrollment
Unknown
Registered
2019-04-23
Start date
2019-04-13
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Total knee arthroplasty

Interventions

Sponsors

Guanghua Hospital, Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
55 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) The primary unilateral total knee arthroplasty is required for the end stage of primary OA or RA; 2) Aged 55-80 years old; 3) perioperative patients receiving tranexamic acid antifibrinolytic therapy; 4) Preoperative hemoglobin, normal coagulation function.

Exclusion criteria

Exclusion criteria: 1) Patients with secondary osteoarthritis other than primary knee osteoarthritis or rheumatoid arthritis (eg post-traumatic osteoarthritis, gouty osteoarthritis, hemophilic osteoarthritis, tuberculosis, Arthritis, ankylosing spondylitis, etc.); 2) Primary OA or RA requiring bilateral total knee arthroplasty; 3) suffering from severe cardiovascular diseases (such as myocardial infarction, atrial fibrillation, angina pectoris, heart failure, etc.), cerebrovascular diseases (cerebral infarction, cerebral hemorrhage, etc.), requiring long-term oral anticoagulant drugs (such as aspirin, warfarin) , clopidogrel, etc.); 4) Diagnosis of hemophilia or coagulopathy.

Design outcomes

Primary

MeasureTime frame
Hematocrit;Hemoglobin;

Countries

China

Contacts

Public ContactXiao Lianbo

Guanghua Hospital, Shanghai University of Traditional Chinese Medicine

xiao_lianbo@163.com+86 18621697913

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026